Published: Fri, March 24, 2017
Medicine | By Megan Pierce

Revenue Estimates Analysis Of Bristol-Myers Squibb Company (BMY)


Bristol-Myers Squibb Company (BMY) stock price ended its day with gain 1.17% and finalized at the price of $56.36. "Ultimately, through all this investigation into the company's performance the analyst decides whether their stock is a "buy", sell" or hold". American Trust Investment Advisors LLC's holdings in Bristol-Myers Squibb were worth $228,000 as of its most recent SEC filing. The company's P/E is 20.21 and Forward P/E ratio is 16.38. In this case, shares are 21.21% higher from $46.01, the worst price in 52 weeks suffered on January 26, 2017, and are keeping their losses at 1.07% for the past six months. The company was founded in August 1933 and is headquartered in New York, NY. State of Alaska Department of Revenue bought a new position in Bristol-Myers Squibb during the third quarter valued at about $109,000. Performance year to date since the 06/01/1972 is -2.92%. Institutional investors own 69.67% of the company's stock. The stock, after opening at $55.70, closed at $56.36 by scoring 1.17%. The firm has a 50-day moving average of $54.63 and a 200 day moving average of $54.84. The total market capitalization remained at $94.27 billion.

Bristol-Myers Squibb Company (NYSE:BMY), stock is trading $76.09 above the 52-week high and has displayed a high EPS growth of 4.20% in last 5 years. We would note that analysts seem to be projecting earnings, on average, for this quarter in the range of $0.66 to $0.80. The firm had revenue of $5.24 billion for the quarter, compared to analysts' expectations of $5.14 billion. Bristol-Myers Squibb had a net margin of 22.94% and a return on equity of 31.39%. On a year-over-year basis, that compares with an EPS comp of $0.74. Finally comes the ratings part in which the CYH was evaluated with 2 analysts of WSJ going for Buy ratings in previous quarter, while at present 1 analyst gave Buy ratings from whole pool.

The business also recently disclosed a quarterly dividend, which will be paid on Monday, May 1st. Stockholders of record on Friday, April 7th will be given a dividend of $0.39 per share. The ex-dividend date is Wednesday, April 5th. Bristol-Myers Squibb's payout ratio is 58.87%.

Several equities research analysts have recently weighed in on BMY shares.

The company has PEG ratio of 1.45 and price to cash ratio of 14.69.

WARNING: "Guardian Capital Advisors LP Buys Shares of 9,207 Bristol-Myers Squibb Co (BMY)" was first published by Chaffey Breeze and is the property of of Chaffey Breeze. Vetr upgraded shares of Bristol-Myers Squibb from a "sell" rating to a "hold" rating and set a $57.15 price objective for the company in a research note on Tuesday, March 14th. Argus restated a "buy" rating and set a $75.00 price objective on shares of Bristol-Myers Squibb in a research report on Wednesday, February 22nd. One investment analyst has rated the stock with a sell rating, twelve have given a hold rating and ten have issued a buy rating to the company's stock. The stock now has an average rating of "Hold" and a consensus price target of $61.83.

In the last 30 days, insiders have sold $6.87M worth of BMY shares and purchased $18.41M worth of BMY shares.

The stock subtracted in the prior trading session by -1.05%, closing at the stock price of $55.77. The Insider selling transaction was reported by the company on Mar 22, 2017 to the Securities and Exchange Commission. The Shares Float shows a value of 1670.38 . Similar statistics are true for the second largest owner, Vanguard Group Inc, which owns 114,811,204 shares of the stock are valued at $6.4 billion. The disclosure for this sale can be found here.

Like this: